Shares of Opus Genetics (IRD) surged 12.8% to $4.57 after the company reported its first meaningful clinical results from two gene therapy programs aimed at rare forms of inherited blindness. For a $350 million company burning cash and generating almost no revenue, the data carry outsized weight — they are the earliest proof that the science might actually work in humans.
Three Out of Four Patients Responded, but These Are Still Small Numbers. The low-dose group of the company's trial for a form of inherited retinal disease caused by BEST1 gene mutations showed improved retinal sensitivity in three of four evaluable participants.
The trial has now completed enrollment in its higher-dose group with 11 participants. A 75% response rate sounds impressive, but four patients is a whisper, not a verdict. Investors are essentially betting that the signal holds as the sample size grows.
A Second Program Is Closer to the Finish Line. The company's treatment for Leber congenital amaurosis type 5 — a rare childhood-onset blindness — showed improvements in visual sharpness through 24 months in adults and through six months in adolescents. Crucially, dosing for the Phase 3 trial — the final stage before seeking regulatory approval — is expected to begin in the fourth quarter of 2026. That makes this the company's nearest-term shot at an approvable product.
Cash Runway Buys Time, but the Burn Is Real. As of June 30, 2026, Opus held $88.8 million in cash and projects a runway into 2029.
Trailing revenue was just $14.2 million over the past year, while net losses totaled $49.6 million. The company filed a $300 million shelf registration in August — a mechanism to sell new stock — signaling it may need to raise more money. Short interest stands at 10.8 million shares, roughly 14.7% of the float , meaning a chunk of professional traders are betting the stock will fall.
Analyst Optimism Far Outpaces the Stock Price. Jones Trading recently raised its price target to $17 , nearly four times the current price. All six analysts covering the stock rate it a Buy. That consensus reflects confidence in the pipeline's potential, but also the vast distance between today's early-stage data and future commercial sales. The target patient pool for the lead program is estimated at only 3,240 patients globally , underscoring how niche these diseases are — and how high prices per treatment would need to be to justify the valuation.